INO-4800 COVID-19 Vaccine Candidate: Dark Horse Contender?

INO-4800 COVID-19 Vaccine Candidate: Dark Horse Contender?

Inovio Pharmaceuticals was co-founded by an individual known in scientific circles as “the father of DNA vaccines.” David Weiner, head of Wistar Institute’s Weiner Laboratory, has spent decades working toward this moment in history. Although Inovio’s INO-4800 hasn’t been considered a primary vaccine contender, the company was featured on 60 Minutes and recently, the firm secured $71 million in government funds to manufacture the electro-device that is part of its COVID-19 vaccine platform. To date, not a single human DNA vaccine has been commercialized worldwide.   

Leading the Pack?

Industry, media, purported experts, and some investors are leaning toward Moderna (mRNA-1273), which is preparing for their Phase 3 clinical trial, however University of Oxford partnered with AstraZeneca to take the vaccine to Phase 3 and hopefully commercialization. The U.S. government place a $483 million bet on Moderna and a $1 billion on the AstraZeneca and Oxford partnership. University of Oxford and AstraZeneca have progressed AZD1222 to the critical Phase 2/3 clinical trial stage involving a 10, 260 participant study in the UK. CanSino Biologics from China has inked a deal with the Canadi...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee